Daily online adaptive radiotherapy for anal cancer
ROAR-A: Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer
This study is testing if daily online adaptive radiotherapy can help people with anal cancer experience less stomach problems compared to standard radiation treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 205 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Herlev Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Herlev) |
| Trial ID | NCT05438836 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of daily online adaptive radiotherapy (oART) for patients with anal cancer. It aims to determine if this approach can significantly reduce early gastrointestinal toxicity compared to traditional non-adaptive intensity modulated radiation therapy (IMRT). The study is a single-arm, prospective trial conducted at a single center, focusing on patients who are eligible for curative radiotherapy. Participants will receive daily adjustments to their treatment based on real-time imaging and anatomical changes.
Who should consider this trial
Good fit: Ideal candidates include individuals with biopsy-verified anal cancer who are eligible for curative radiotherapy.
Not a fit: Patients with other malignant diseases within the past five years may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to reduced side effects from treatment, improving the quality of life for patients with anal cancer.
How similar studies have performed: Other studies have shown promise with adaptive radiotherapy approaches, suggesting potential benefits in reducing treatment-related toxicities.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Biopsy-verified anal cancer * Eligible for curative intended radiotherapy * Written and oral consent Exclusion Criteria: * Other malignant disease within the past 5 years (excluding basal cell carcinoma)
Where this trial is running
Herlev
- Oncology dept, Herlev and Gentofte Hospital — Herlev, Denmark (Recruiting)
Study contacts
- Principal investigator: Eva S Serup-Hansen, MD, PhD — Herlev og Gentofte Hospital
- Study coordinator: Eva Serup-Hansen, MD, PhD
- Email: eva.serup-hansen@regionh.dk
- Phone: +4538689084
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.